Amoy Diagnostics Co., Ltd. (SHE:300685)
China · Delayed Price · Currency is CNY 21.33
-0.05 (-0.23%)
Feb 4, 2026, 3:04 PM CST
Amoy Diagnostics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,122 | 1,104 | 1,034 | 832.43 | 908.12 | 723.27 |
Other Revenue | 4.64 | 4.64 | 9.99 | 9.75 | 8.91 | 5.12 |
| 1,127 | 1,109 | 1,044 | 842.18 | 917.03 | 728.39 | |
Revenue Growth (YoY) | -4.84% | 6.27% | 23.91% | -8.16% | 25.90% | 25.94% |
Cost of Revenue | 192.62 | 181.34 | 176.92 | 153.44 | 147.19 | 94.94 |
Gross Profit | 933.99 | 927.61 | 866.58 | 688.74 | 769.84 | 633.45 |
Selling, General & Admin | 411.43 | 418.83 | 384.71 | 360.44 | 364.31 | 329.91 |
Research & Development | 184.13 | 216.11 | 203.22 | 174.53 | 156.12 | 115.11 |
Other Operating Expenses | 22.28 | 4.66 | 4.07 | 3.14 | 4.18 | 3.36 |
Operating Expenses | 647.62 | 650.35 | 597.12 | 545.1 | 534.79 | 457.5 |
Operating Income | 286.37 | 277.25 | 269.46 | 143.64 | 235.05 | 175.95 |
Interest Expense | -1.87 | -1.34 | -1.2 | -0.99 | -0.38 | -0.86 |
Interest & Investment Income | 39.88 | 26.58 | 19.17 | 6.11 | 5.59 | 7.66 |
Currency Exchange Gain (Loss) | 2.42 | 2.42 | 8.25 | 25.32 | -9.48 | -13.87 |
Other Non Operating Income (Expenses) | -5.74 | -18.45 | -0.33 | -2.08 | -0.48 | -1.95 |
EBT Excluding Unusual Items | 321.07 | 286.46 | 295.35 | 171.99 | 230.3 | 166.93 |
Gain (Loss) on Sale of Investments | -10.12 | -8.71 | -15.69 | 1.98 | 5.85 | 0.36 |
Gain (Loss) on Sale of Assets | -1.09 | -1.06 | -0.96 | 94.58 | -1.96 | 0.09 |
Asset Writedown | 7.91 | -0.06 | -0.04 | -0.61 | -0.27 | - |
Other Unusual Items | 21.82 | 13.26 | 16.19 | 18.15 | 18.06 | 33.33 |
Pretax Income | 339.59 | 289.88 | 294.86 | 286.08 | 251.98 | 200.71 |
Income Tax Expense | 49.49 | 35.02 | 33.37 | 21.79 | 12.95 | 20.38 |
Earnings From Continuing Operations | 290.1 | 254.86 | 261.48 | 264.29 | 239.02 | 180.33 |
Minority Interest in Earnings | - | - | - | -0.55 | 0.55 | - |
Net Income | 290.1 | 254.86 | 261.48 | 263.74 | 239.57 | 180.33 |
Net Income to Common | 290.1 | 254.86 | 261.48 | 263.74 | 239.57 | 180.33 |
Net Income Growth | -7.91% | -2.53% | -0.86% | 10.09% | 32.86% | 33.11% |
Shares Outstanding (Basic) | 393 | 398 | 396 | 394 | 399 | 396 |
Shares Outstanding (Diluted) | 393 | 398 | 396 | 394 | 399 | 401 |
Shares Change (YoY) | -1.52% | 0.51% | 0.65% | -1.41% | -0.36% | 2.97% |
EPS (Basic) | 0.74 | 0.64 | 0.66 | 0.67 | 0.60 | 0.46 |
EPS (Diluted) | 0.74 | 0.64 | 0.66 | 0.67 | 0.60 | 0.45 |
EPS Growth | -6.49% | -3.03% | -1.49% | 11.67% | 33.33% | 29.27% |
Free Cash Flow | 307.82 | 301.64 | 253.85 | 70.75 | 93.61 | 162.8 |
Free Cash Flow Per Share | 0.78 | 0.76 | 0.64 | 0.18 | 0.23 | 0.41 |
Dividend Per Share | 0.300 | 0.300 | 0.150 | 0.140 | 0.128 | 0.139 |
Dividend Growth | 100.00% | 100.00% | 7.14% | 9.55% | -7.99% | 50.00% |
Gross Margin | 82.90% | 83.65% | 83.05% | 81.78% | 83.95% | 86.97% |
Operating Margin | 25.42% | 25.00% | 25.82% | 17.06% | 25.63% | 24.16% |
Profit Margin | 25.75% | 22.98% | 25.06% | 31.32% | 26.13% | 24.76% |
Free Cash Flow Margin | 27.32% | 27.20% | 24.33% | 8.40% | 10.21% | 22.35% |
EBITDA | 327.28 | 323.25 | 322.24 | 191.46 | 271.49 | 203.27 |
EBITDA Margin | 29.05% | 29.15% | 30.88% | 22.73% | 29.61% | 27.91% |
D&A For EBITDA | 40.91 | 45.99 | 52.78 | 47.82 | 36.45 | 27.32 |
EBIT | 286.37 | 277.25 | 269.46 | 143.64 | 235.05 | 175.95 |
EBIT Margin | 25.42% | 25.00% | 25.82% | 17.06% | 25.63% | 24.16% |
Effective Tax Rate | 14.57% | 12.08% | 11.32% | 7.62% | 5.14% | 10.15% |
Revenue as Reported | 1,127 | 1,109 | 1,044 | 842.18 | 917.03 | 728.39 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.